Literature DB >> 15801737

Identification of molecular target of AMP-activated protein kinase activator by affinity purification and mass spectrometry.

Toshiyuki Kosaka1, Ryo Okuyama, Weiyong Sun, Tsuneaki Ogata, Jun Harada, Kazushi Araki, Masanori Izumi, Taishi Yoshida, Akira Okuno, Toshihiko Fujiwara, Jun Ohsumi, Kimihisa Ichikawa.   

Abstract

We show an efficient method to identify molecular targets of small molecular compounds by affinity purification and mass spectrometry. Binding proteins were isolated from target cell lysate using affinity columns, which immobilized the active and inactive compounds. All proteins bound to these affinity columns were eluted by digestion using trypsin and then were identified by mass spectrometry. The specific binding proteins to the active compound, a candidate for molecular targets, were determined by subtracting the identified proteins in an inactive compound-immobilized affinity column from that in an active compound-immobilized affinity column. This method was applied to identification of molecular targets of D942, a furancarboxylic acid derivative, which increases glucose uptake in L6 myocytes through AMP-activated protein kinase (AMPK) activation. To elucidate the mechanism of AMPK activation by D942, affinity columns that immobilized D942 and its inactive derivative, D768, were prepared, and the binding proteins were purified from L6 cell lysate. NAD(P)H dehydrogenase [quinone] 1 (complex I), which was shown as one of the specific binding proteins to D942 by subtracting the binding proteins to D768, was partially inhibited by D942, not D768. Because inhibition of complex I activity led to a decrease in the ATP/AMP ratio, and the change in the ATP/AMP ratio triggered AMPK activation, we identified complex I as a potential protein target of AMPK activation by D942. This result shows our approach can provide crucial information about the molecular targets of small molecular compounds, especially target proteins not yet identified.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15801737     DOI: 10.1021/ac0484631

Source DB:  PubMed          Journal:  Anal Chem        ISSN: 0003-2700            Impact factor:   6.986


  10 in total

1.  Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice.

Authors:  A Maida; B J Lamont; X Cao; D J Drucker
Journal:  Diabetologia       Date:  2010-10-23       Impact factor: 10.122

2.  Arctigenin, a natural compound, activates AMP-activated protein kinase via inhibition of mitochondria complex I and ameliorates metabolic disorders in ob/ob mice.

Authors:  S-L Huang; R-T Yu; J Gong; Y Feng; Y-L Dai; F Hu; Y-H Hu; Y-D Tao; Y Leng
Journal:  Diabetologia       Date:  2011-11-18       Impact factor: 10.122

Review 3.  Phenotypic drug discovery: recent successes, lessons learned and new directions.

Authors:  Fabien Vincent; Arsenio Nueda; Jonathan Lee; Monica Schenone; Marco Prunotto; Mark Mercola
Journal:  Nat Rev Drug Discov       Date:  2022-05-30       Impact factor: 112.288

4.  CCL2 is a negative regulator of AMP-activated protein kinase to sustain mTOR complex-1 activation, survivin expression, and cell survival in human prostate cancer PC3 cells.

Authors:  Hernan Roca; Zachary S Varsos; Kenneth J Pienta
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

5.  Glucose restriction inhibits skeletal myoblast differentiation by activating SIRT1 through AMPK-mediated regulation of Nampt.

Authors:  Marcella Fulco; Yana Cen; Po Zhao; Eric P Hoffman; Michael W McBurney; Anthony A Sauve; Vittorio Sartorelli
Journal:  Dev Cell       Date:  2008-05       Impact factor: 12.270

6.  Small molecule antagonizes autoinhibition and activates AMP-activated protein kinase in cells.

Authors:  Tao Pang; Zhen-Shan Zhang; Min Gu; Bei-Ying Qiu; Li-Fang Yu; Peng-Rong Cao; Wei Shao; Ming-Bo Su; Jing-Ya Li; Fa-Jun Nan; Jia Li
Journal:  J Biol Chem       Date:  2008-03-05       Impact factor: 5.157

7.  Adenosine Monophosphate-Activated Protein Kinase (AMPK) as a New Target for Antidiabetic Drugs: A Review on Metabolic, Pharmacological and Chemical Considerations.

Authors:  Arie Gruzman; Gali Babai; Shlomo Sasson
Journal:  Rev Diabet Stud       Date:  2009-05-10

8.  Pre-treatment with D942, a furancarboxylic acid derivative, increases desiccation tolerance in an anhydrobiotic tardigrade Hypsibius exemplaris.

Authors:  Koyuki Kondo; Masaru Mori; Masaru Tomita; Kazuharu Arakawa
Journal:  FEBS Open Bio       Date:  2020-07-22       Impact factor: 2.693

9.  High-throughput assay for modulators of mitochondrial membrane potential identifies a novel compound with beneficial effects on db/db mice.

Authors:  Bei-Ying Qiu; Nigel Turner; Yuan-Yuan Li; Min Gu; Meng-Wei Huang; Fang Wu; Tao Pang; Fa-Jun Nan; Ji-Ming Ye; Jing-Ya Li; Jia Li
Journal:  Diabetes       Date:  2009-10-15       Impact factor: 9.461

10.  Tubulin is a molecular target of the Wnt-activating chemical probe.

Authors:  Yasunori Fukuda; Osamu Sano; Kenichi Kazetani; Koji Yamamoto; Hidehisa Iwata; Junji Matsui
Journal:  BMC Biochem       Date:  2016-05-20       Impact factor: 4.059

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.